Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 9/20 | 0.65 |
| ▸ | EGFR | P00533 | 2/20 | 0.63 |
| ▸ | PLK1 | P53350 | 3/20 | 0.60 |
| ▸ | BRD4 | O60885 | 4/20 | 0.60 |
| ▸ | PAK4 | O96013 | 1/20 | 0.52 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.52 |
| ▸ | CDK4 | P11802 | 1/20 | 0.52 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.52 |
| ▸ | CCND1 | P24385 | 1/20 | 0.52 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.52 |
| ▸ | CDK2 | P24941 | 1/20 | 0.52 |
| ▸ | CCND2 | P30279 | 1/20 | 0.52 |
| ▸ | CCND3 | P30281 | 1/20 | 0.52 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.52 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.52 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.52 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12639219 | 0.99 | SYK (0.64) | SYKEGFRPLK1BRD4PAK4 | |
| SCHEMBL14847372 | 0.96 | SYK (0.67) | SYKEGFRPLK1BRD4ALK | |
| SCHEMBL5511671 | 0.90 | SYK (0.54) | SYKEGFRPLK1 | |
| SCHEMBL5520583 | 0.89 | SYK (0.65) | SYKCCNE2CDK4CCNA2CCND1 | |
| SCHEMBL14001913 | 0.89 | SYK (0.64) | SYKCCNE2CDK4CCNA2CCND1 | |
| SCHEMBL15153277 | 0.86 | SYK (0.51) | SYKEGFRPLK1BRD4ALK | |
| SCHEMBL12064871 | 0.86 | EGFR (0.69) | SYKEGFRPLK1BRD4CCNA2 | |
| SCHEMBL15153360 | 0.85 | EGFR (0.59) | SYKEGFRPLK1BRD4CCNE2 | |
| SCHEMBL16120467 | 0.85 | SYK (0.61) | SYKEGFRBRD4PAK4CCNE2 | |
| SCHEMBL17709573 | 0.85 | SYK (0.61) | SYKEGFRBRD4PAK4CCNE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2578584-B1 | ARYLAMINO PURINE DERIVATIVES, PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF | SI CHUAN UNIV (CN) | 2020-08-12 | — | — | EP | disclosed |
| US-9096601-B2 | Arylamino purine derivatives, preparation method and pharmaceutical use thereof | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) | 2015-08-04 | — | — | US | disclosed |
| US-9096601-B2 | Arylamino purine derivatives, preparation method and pharmaceutical use thereof | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) | 2015-08-04 | — | — | US | disclosed |
| US-9096601-B2 | Arylamino purine derivatives, preparation method and pharmaceutical use thereof | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) | 2015-08-04 | — | — | US | disclosed |
| US-20130203986-A1 | Arylamino Purine Derivatives, Preparation Method and Pharmaceutical Use Thereof | SI Chuaan University (CN) | 2013-08-08 | — | — | US | disclosed |
| US-20130203986-A1 | Arylamino Purine Derivatives, Preparation Method and Pharmaceutical Use Thereof | SI Chuaan University (CN) | 2013-08-08 | — | — | US | disclosed |
| US-20130203986-A1 | Arylamino Purine Derivatives, Preparation Method and Pharmaceutical Use Thereof | SI Chuaan University (CN) | 2013-08-08 | — | — | US | disclosed |
| EP-2578584-A1 | ARYLAMINO PURINE DERIVATIVES, PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF | Si Chuan University (CN) | 2013-04-10 | — | — | EP | disclosed |
| US-20070049600-A1 | PTERIDINONES AS KINASE INHIBITORS | WARNER-LAMBERT COMPANY | 2007-03-01 | — | — | US | disclosed |
| US-20070049600-A1 | PTERIDINONES AS KINASE INHIBITORS | WARNER-LAMBERT COMPANY | 2007-03-01 | — | — | US | disclosed |
| US-20070049600-A1 | PTERIDINONES AS KINASE INHIBITORS | WARNER-LAMBERT COMPANY | 2007-03-01 | — | — | US | disclosed |
| US-7169778-B2 | Pteridinones as kinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2007-01-30 | — | — | US | disclosed |
| US-7169778-B2 | Pteridinones as kinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2007-01-30 | — | — | US | disclosed |
| US-7169778-B2 | Pteridinones as kinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2007-01-30 | — | — | US | disclosed |
| EP-1409487-A1 | PTERIDINONES AS KINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-04-21 | — | — | EP | disclosed |
| US-20030130286-A1 | Pteridinones as kinase inhibitors | DENNY WILLIAM ALEXANDER (NZ) | 2003-07-10 | — | — | US | disclosed |
| CN-1373763-A | Pteridinones and kinase inhibitors | WARNER LAMBERT CO (US) | 2002-10-09 | — | — | CN | disclosed |
| WO-2001019825-A1 | PTERIDINONES AS KINASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2001-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130203986-A1 | Arylamino Purine Derivatives, Preparation Method and Pharmaceutical Use Thereof | EGFR, PNP, GART | SYK 1238/4885EGFR 1/4885PLK1 1742/4885 |
| US-20030130286-A1 | Pteridinones as kinase inhibitors | CCNI, CCNK, CDK2 | SYK 1655/4885EGFR 128/4885PLK1 127/4885 |
| US-20070049600-A1 | PTERIDINONES AS KINASE INHIBITORS | CCNI, CCNK, CDK2 | SYK 521/4885EGFR 70/4885PLK1 103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.